(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/199356 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) *A61K 31/7125* (2006.01)
A61K 31/7115 (2006.01) *A61K 31/713* (2006.01)
A61K 31/712 (2006.01) *A61P 7/00* (2006.01)

(21) International Application Number:
PCT/US2025/020752

(22) International Filing Date:
20 March 2025 (20.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/569,039 22 March 2024 (22.03.2024) US
63/714,671 31 October 2024 (31.10.2024) US

(71) Applicant: **SIRIUS THERAPEUTICS, INC.** [US/US]; 11760 Sorrento Valley Road, San Diego, California 92121 (US).

(72) Inventors: **BRADSHAW, Curt W.**; 11760 Sorrento Valley Road, San Diego, California 92121 (US). **NICHOLAS, Anthony**; 11760 Sorrento Valley Road, San Diego, California 92121 (US).


(74) Agent: **SHIN, Minyoung** et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF

FIG. 9



(57) Abstract: Disclosed herein are polynucleic acid molecules that can be utilized for suppressing the expression of coagulation factor XI (*FXI*) gene. Also, described herein are pharmaceutical compositions comprising polynucleic acid molecules targeting coagulation factor XI (FXI) mRNA. Further provided herein are methods for suppressing the expression of coagulation factor XI (*FXI*) by utilizing the polynucleic acid molecules described herein.

[Continued on next page]

WO 2025/199356 A1

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*